{"id":2621,"date":"2019-01-01T12:02:00","date_gmt":"2019-01-01T11:02:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2019\/ist-fischoel-doch-protektiv-wirksam-bei-kardiovaskulaeren-erkrankungen"},"modified":"2019-01-01T12:02:00","modified_gmt":"2019-01-01T11:02:00","slug":"ist-fischoel-doch-protektiv-wirksam-bei-kardiovaskulaeren-erkrankungen","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2019\/ist-fischoel-doch-protektiv-wirksam-bei-kardiovaskulaeren-erkrankungen","title":{"rendered":"Ist Fisch\u00f6l doch protektiv wirksam bei kardiovaskul\u00e4ren Erkrankungen?"},"content":{"rendered":"<p>\u201cWe welcome these results with surprise, speculation and hope\u201d. Mit diesen Worten kommentieren die beiden Atheroskleroseforscher John Kastelein und Erik Stroes aus Amsterdam die Ergebnisse der am 10. November im N. Engl. J. Med. ver\u00f6ffentlichten REDUCE-IT-Studie (1, 2). Die industrielastige Studie testete ein spezielles Fisch\u00f6lpr\u00e4parat an kardiovaskul\u00e4ren Hochrisikopatienten mit erh\u00f6hten Triglyzerid (TG)-Werten. Ziel der Studie [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u201cWe welcome these results with surprise, speculation and hope\u201d. Mit diesen Worten kommentieren die beiden Atheroskleroseforscher John Kastelein und Erik Stroes aus Amsterdam die Ergebnisse der am 10. November im N. Engl. J. Med. ver\u00f6ffentlichten REDUCE-IT-Studie (1, 2). Die industrielastige Studie testete ein spezielles Fisch\u00f6lpr\u00e4parat an kardiovaskul\u00e4ren Hochrisikopatienten mit erh\u00f6hten Triglyzerid (TG)-Werten. Ziel der Studie [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[60,1272,2672,1480,2671,71,68,5161,498,65,2615,4805,5160,56],"class_list":["post-2621","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-apoplektischer-insult","tag-arteriosklerose","tag-eicosapentaensaeure","tag-fettsaeuren","tag-fischoel","tag-herzinfarkt","tag-hirninfarkt","tag-jelis-studie","tag-koronare-herzkrankheit","tag-myokardinfarkt","tag-omega-3-fettsaeuren","tag-pufa","tag-reduce-it-studie","tag-schlaganfall"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2621","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2621"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2621\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2621"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2621"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2621"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}